Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Smolle, MA; Andreou, D; Wölfel, J; Acem, I; Aj, Van, De, Sande, M; Jeys, L; Bonenkamp, H; Pollock, R; Tunn, PU; Haas, R; Posch, F; Van, Ginkel, RJ; Verhoef, C; Liegl-Atzwanger, B; Moustafa-Hubmer, D; Jost, PJ; Leithner, A; Szkandera, J.
Effect of radiotherapy on local recurrence, distant metastasis and overall survival in 1200 extremity soft tissue sarcoma patients. Retrospective analysis using IPTW-adjusted models.
Radiother Oncol. 2023; 189:109944
Doi: 10.1016/j.radonc.2023.109944
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Smolle Maria Anna
- Co-Autor*innen der Med Uni Graz
- Andreou Dimosthenis
- Jost Philipp
- Leithner Andreas
- Liegl-Atzwanger Bernadette
- Posch Florian
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND PURPOSE: Neoadjuvant (NRTX) and adjuvant radiotherapy (ARTX) reduce local recurrence (LR) risk in extremity soft tissue sarcoma (eSTS), yet their impact on distant metastasis (DM) and overall survival (OS) is less well defined. This study aimed at analysing the influence of NRTX/ARTX on all three endpoints using a retrospective, multicentre eSTS cohort. MATERIALS AND METHODS: 1200 patients (mean age: 60.7 ± 16.8 years; 44.4 % females) were retrospectively included, treated with limb sparing surgery and curative intent for localised, high grade (G2/3) eSTS. 194 (16.2 %), 790 (65.8 %), and 216 (18.0 %) patients had received NRTX, ARTX and no RTX, respectively. For the resulting three groups (no RTX vs. NRTX, no RTX vs. ARTX, NRTX vs. ARTX) Fine&Gray models for LR and DM, and Cox-regression models for OS were calculated, with IPTW-modelling adjusting for imbalances between groups. RESULTS: In the IPTW-adjusted analysis, NRTX was associated with lower LR-risk in comparison to no RTX (SHR [subhazard ratio]: 0.236; p = 0.003), whilst no impact on DM-risk (p = 0.576) or OS (p = 1.000) was found. IPTW-weighted analysis for no RTX vs. ARTX revealed a significant positive association between ARTX and lower LR-risk (SHR: 0.479, p = 0.003), but again no impact on DM-risk (p = 0.363) or OS (p = 0.534). IPTW-weighted model for NRTX vs. ARTX showed significantly lower LR-risk for NRTX (SHR for ARTX: 3.433; p = 0.003) but no difference regarding DM-risk (p = 1.000) or OS (p = 0.639). CONCLUSION: NRTX and ARTX are associated with lower LR-risk, but do not seem to affect DM-risk or OS. NRTX may be favoured over ARTX as our results indicate better local control rates.
- Find related publications in this database (using NLM MeSH Indexing)
- Female - administration & dosage
- Humans - administration & dosage
- Adult - administration & dosage
- Middle Aged - administration & dosage
- Aged - administration & dosage
- Male - administration & dosage
- Retrospective Studies - administration & dosage
- Sarcoma - administration & dosage
- Radiotherapy, Adjuvant - administration & dosage
- Neoadjuvant Therapy - administration & dosage
- Neoplasm Recurrence, Local - pathology
- Extremities - pathology
- Find related publications in this database (Keywords)
- Soft Tissue Sarcoma
- Neoadjuvant radiotherapy
- Adjuvant radiotherapy
- Local recurrence
- Distant Metastasis
- Overall survival